Key facts
- A novel CAR T cell therapy trial has enabled kidney failure patients to receive transplants.
- Three patients with end-stage kidney failure received transplants after CAR T cell therapy.
- The therapy desensitizes patients, making previously incompatible kidneys viable.
- The trial was co-led by NYU Langone researchers.
- The therapy is a novel phase 1 clinical trial.
A pioneering clinical trial co-led by NYU Langone researchers has demonstrated that CAR T cell therapy can safely desensitize even the most challenging transplant candidates. The novel phase 1 trial successfully enabled three patients with end-stage kidney failure, who were previously unable to receive transplants due to blood type incompatibility, to undergo successful kidney transplants. This breakthrough offers hope for many patients who were previously excluded from the transplant waiting list. Researchers are optimistic about the therapy's potential to help more patients in the future.